Donor lymphocyte infusion (DLI) may have a potential therapeutic role in allograft recipients with life-threatening opportunistic infections. We report a successful treatment outcome in a patient with invasive fungal pneumonia. The patient who was refractory to prolonged course of liposomal Amphothericin cleared his infection after institution of posaconazole given in conjunction with four sequential DLI. This observed clinical benefit was associated with increasing number of circulating CD4 þ and CD8 þ T cells post-DLI.
A 66-year-old Caucasian man with history of AML in CR-2 underwent allogeneic peripheral blood SCT from 9/10-matched brother. His myeloablative-conditioning regimen included busulfan, fludarabine, anti-T-lymphocyte globulin (ATG) and high-dose methylprednisolone. A total of 3.44 Â 10 6 CD34 þ cells/kg and 3.26 Â 10 8 CD3 þ cells/ kg were infused during SCT. For GVHD prophylaxis, the patient received tacrolimus and low-dose methotrexate. His myeloid engraftment was completed on day þ 12. Patient's post-transplantation course was significant for grade II acute GVHD of skin, delayed platelet and red cell engraftment, multiple bacterial infections including a complicated pneumonia. Short tandem repeat (STR) analysis on BM samples on days þ 35 and þ 100 showed 100% donor chimerism in both lymphoid and myeloid lineages. His GVHD prophylaxis had been tapered off and discontinued by day þ 180.
On day þ 167 post-transplant, he developed multiple nodular consolidations in his right lower lobe (RLL) of the lung. Bronchoscopy/BAL revealed respiratory syncytial virus (RSV) infection. His absolute CD4 and CD8 counts were 30 and 98 /mcl, respectively and IgG level was 494 mg/ dl at that time. On the basis of radiologic appearance of persistent nodular infiltrate, a coexisting fungal infection was suspected. Therefore, he was started on amphotericin-B lipid formulation (liposomal ampho-B). Of note, the patient had been on voriconazole prophylaxis for the entire post-transplant course. He cleared off his RSV infection but a follow-up computed tomography (CT) scan of chest showed persistent RLL nodular consolidation.
He continued to have low-grade fever, persistent cough, pleuretic chest pain and nodular infiltrate in the CT scan despite a 2-month course of liposomal ampho-B. A second bronchoscopy/BAL and a transbronchial biopsy were all negative for microorganism. Mycafungin was added. However, no major change in his symptoms as well as in the RLL nodular lesions was observed. His absolute CD4 counts remained less than 100/mcl despite being off of immunosuppressive therapy.
He eventually underwent a wedge lung resection of the RLL lesion. Histopathologic examination revealed angioinvasive fungal necrotizing granulomas (Figure 1a ), consistent with aspergillus infection. Fungal cultures failed to identify the exact species of the organism. He had persistent RLL consolidation with pleural effusion after surgery. He later became increasingly dyspneic, requiring oxygen despite 3-month course of antifungal treatment. He also had persistent intractable cough and chest pain. Another CT scan of the chest revealed interval increase in persistent nodular consolidation with increasing pleural effusion (Figure 1b) .
He was enrolled in a protocol and started on posaconazole at a dose of 400 mg orally q.i.d. (four times daily) Â 1 week followed by 400 mg BID thereafter to complete 2-month course of treatment. Given no evidence of GVHD, we also started DLI in conjunction with posaconazole. A total of four consecutive DLIs at a fixed dose of 1 Â 10 6 CD3 þ cells/kg on weeks 0, 2, 6 and 10 were given, in an attempt to augment nonspecific T-cell response against refractory fungal pneumonia. He received twice weekly GM-CSF injections at 5 mcg/kg because of ongoing leukopenia. He was supported with RBC and platelet transfusions. All three BM examinations showed hypocellular marrow (30%) with no evidence of leukemia and 100% donor chimerism by STR.
Patient tolerated low-dose DLIs well. He developed nausea and vomiting secondary to posaconazole. His cough, dyspnea and pleuretic chest pain gradually resolved with near complete resolution of RLL infiltrate after 2-month course of treatment (Figure 1c) . In parallel to the clinical improvement, his absolute CD4 and CD8 counts showed gradual increment post-DLI (Figure 1d ). At the time of reporting, the patient remains alive with no leukemia, no GVHD and normal blood counts on day þ 710 after transplant.
Reconstitution of T-cell immunity after myeloablative allogeneic SCT is often delayed, resulting in a prolonged period of immunodeficiency and high mortality from opportunistic viral and fungal infections. One potential approach to reduce the severity of post-transplant immunodeficiency status is to infuse DL. DLI is a form of cell therapy used widely to induce disease remission in patients who relapse following allogeneic SCT. 1 The potential immunologic benefit of DLI in clinical transplant setting has not been well recognized. Amrolia et al. 2 recently demonstrated that allo-reactive T cell-depleted DL could improve T-cell recovery after haploidentical transplant with low GVHD incidence. The cell dose-10 5 cells/kg was critical in T-cell recovery post transplant. Expansion of the effector memory (CD45RA-negative and CCR7-negative) cells was found to be associated with accelerated T-cell recovery, and this finding suggested durable protective T-cell responses. These T cells were originated from infused allodepleted DLs. Tetramer and enzyme-linked immunospot assays showed cytomegalovirus-and Epstein-Barr virus-specific responses in some patients. DLI may also enhance reconstitution of donor T cells as demonstrated by Belluci et al. 3 TCR Vb repertoire complexity improved more rapidly in patients who received CD4 þ DLI at 6 months after allogeneic BMT. The number of T-cell receptor rearrangement excision circles (TRECs) in CD3 þ T cells increased along with conversion to complete donor hematopoiesis.
To reduce the chance of inducing GVHD or BM aplasia, we chose low-dose sequential DLI approach, which has been previously reported in the literature. In a recent study, 12 CD34 þ selected allograft recipients received 22 prophylactic DLIs on days þ 28, þ 60 and þ 90 after transplant at doses of 2 Â 10 5 , 2 Â 10 5 and 2 Â 10 6 /kg, respectively. This approach resulted in acceptable GVHD rate and improved donor engraftment. 4 de Lima et al. 5 also used prophylactic DLI at higher doses (1 Â 10 7 ) to prevent relapse after reduced intensity allo-SCT. This was associated with high incidence of acute GVHD. 5 More recently, Schmid et al. 6 reported their data on 12 patients who received prophylactic DLI after non-ablative allo-SCT, starting from a median day þ 160 at a dose of 1 Â 10 6 CD3 þ cells/kg, given up to three infusions at 4-6-week intervals with possible cell-dose escalation up to 3 Â 10 7 cells/kg. Leukemia-free survival at 3 years was 92%. Nine patients were complete chimeras at the time of initial DLI. One patient developed grade II GVHD and three had chronic GVHD.
The case described above illustrates an excellent clinical outcome after a combination of cellular and antimicrobial therapy in an allogeneic SCT recipient who had treatmentrefractory invasive fungal pneumonia. The absolute benefit of DLI will remain speculative in this clinical scenario but the clinical improvement seemed to be associated with increasing number of circulating CD4 þ and CD8 þ T cells post-DLI. A further collaborative clinical study may uncover a potential utility of DLI in severe immunodeficiency states in allograft recipients. Letter to the Editor
